Janssen has allied with a consortium of global partners to launch the first efficacy study of an investigational mosaic HIV-1 preventive vaccine.

The company has partnered with the Bill and Melinda Gates Foundation and National Institutes of Health to study the new global vaccine, which is designed to prevent a wide range of viral strains responsible for the HIV pandemic.

“Janssen is partnering with the Bill and Melinda Gates Foundation and National Institutes of Health to assess a new mosaic HIV-1 preventive vaccine.“

Over the course of the Imbokodo study, the team will establish whether Janssen's vaccine regimen is safe and able to reduce the incidence of HIV infection among 2,600 women in sub-Saharan Africa.

The first participants have begun receiving vaccinations at sites in South Africa, with regulatory approvals now being sought to expand the study to additional sites in Malawi, Mozambique, Zambia and Zimbabwe.

Dr Johan Van Hoof, Janssen's therapeutic area head for infectious disease and vaccines research and development, said: "The ultimate goal is to deliver a global vaccine that could be deployed in any geographic region to help protect vulnerable populations at risk of infection."

The launch of this study means that for the first time in over a decade, two vaccine efficacy studies are taking place at the same time, with another study, HVTN 702, currently underway in South Africa to evaluate a different candidate.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.